Rempel, E.
Kluck, K.
Beck, S.
Ourailidis, I. http://orcid.org/0000-0001-6783-5617
Kazdal, D. http://orcid.org/0000-0001-8187-3281
Neumann, O. http://orcid.org/0000-0003-2684-9187
Volckmar, A. L.
Kirchner, M.
Goldschmid, H.
Pfarr, N. http://orcid.org/0000-0002-5977-5375
Weichert, W.
Hübschmann, D. http://orcid.org/0000-0002-6041-7049
Fröhling, S.
Sutter, C. http://orcid.org/0000-0003-4051-5888
Schaaf, C. P.
Schirmacher, P.
Endris, V.
Stenzinger, A. http://orcid.org/0000-0003-1001-103X
Budczies, J. http://orcid.org/0000-0002-6668-5327
Funding for this research was provided by:
Deutsches Krebsforschungszentrum
Centers for Personalized Medicine Baden-Wuerttemberg
Article History
Received: 1 July 2021
Accepted: 15 April 2022
First Online: 9 June 2022
Competing interests
: D.K. reports personal fees for speaker honoraria from AstraZeneca, and Pfizer, personal fees for Advisory Board from Bristol-Myers Squibb, outside the submitted work. A.L.V. reports personal fees from Astra Zeneca, outside the submitted work. N.P. reports non-financial support from Bristol-Myers Squibb, personal fees from Roche, Novartis, Lilly, Bayer, and AstraZeneca, non-financial support from Illumina, and Thermo fisher Scientific. W.W. reports personal fees for participation in Advisory Board/Speaker’s Bureau from Roche, MSD, Bristol-Myers Squibb, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Illumina, Siemens, Agilent, GSK, Eisai and Molecular Health, institutional research grants from Roche, MSD, Bristol-Myers Squibb, and AstraZeneca, outside the submitted work. S.F. reports grants from AstraZeneca, and Pfizer, personal fees from Bayer, and Illumina, grants and personal fees from PharmaMar, and Roche, outside the submitted work. P.S. reports personal fees from BMS, MSD, Incyte, Janssen, Amgen, Novartis, Roche and AstraZeneca outside the submitted work. A.S. reports grants and personal fees from Bayer, BMS, grants from Chugai and personal fees from Astra Zeneca, MSD, Takeda, Seattle Genetics, Novartis, Illumina, Thermo Fisher, Eli Lily, Takeda, outside the submitted work. A.S. reports participation in Advisory Board/Speaker’s Bureau for Astra Zeneca, AGCT, Bayer, Bristol-Myers Squibb, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, and Thermo Fisher, grants from Bayer, Bristol-Myers Squibb, and Chugai, outside the submitted work. J.B. reports grants from German Cancer Aid, outside the submitted work. All remaining authors have declared no conflicts of interest.